Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Coley Seeks HCV Partner For Actilon

This article was originally published in The Pink Sheet Daily

Executive Summary

Firm suspends independent development of the hepatitis C agent in hopes of finding a partner with resources and expertise to share the risk.

You may also be interested in...



Array/VentiRx Partner On Toll-Like Receptor Drugs In Oncology, Allergy

Through a licensing agreement, VentiRx gains rights to Array’s TLR program containing several development candidates

Array/VentiRx Partner On Toll-Like Receptor Drugs In Oncology, Allergy

Through a licensing agreement, VentiRx gains rights to Array’s TLR program containing several development candidates

Anadys/Novartis Hepatitis C Candidate Could Be Back In The Clinic By Year End

A 13-week preclinical toxicology study of ANA975 aims to explain dose dependence and immune stimulation concerns that led to FDA’s clinical hold for the toll-like receptor agonist.

Topics

UsernamePublicRestriction

Register

LL1135415

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel